Quick Summary

Mounjaro and Wegovy are FDA-approved weight loss medications with extensive safety data. When prescribed and monitored by a registered pharmacist, these treatments are safe and effective. Common side effects are usually mild and temporary.

Weight Loss Treatment Safety Information

Medical Review: Reviewed by registered pharmacist. Last Updated: December 2025. Location: Glasgow, Scotland.

Safety Overview

Both Mounjaro and Wegovy are FDA-approved medications for weight loss management. They have undergone extensive clinical trials involving thousands of patients, demonstrating favourable safety profiles when used as prescribed under medical supervision.

At our Glasgow clinic, all prescriptions are provided by a registered pharmacist who assesses your eligibility, monitors your progress, and ensures your safety throughout treatment.

Common Side Effects

Most side effects are mild to moderate and temporary, occurring most often when starting treatment or increasing dosage:

Gastrointestinal: Nausea, vomiting, diarrhoea, constipation, abdominal pain
Appetite: Reduced appetite (intended effect)
Other: Fatigue, dizziness, headache

These side effects typically improve as your body adjusts to the medication. Our pharmacist monitors you throughout treatment and can adjust your dosage or provide guidance on managing side effects.

Serious Side Effects and Contraindications

Treatment is not suitable for everyone. You should not take these medications if you have:

Medullary Thyroid Carcinoma (MTC): Personal or family history
Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
Severe Gastrointestinal Disease: Including gastroparesis
Pregnancy or Breastfeeding: Not recommended during pregnancy or while breastfeeding
Severe Allergic Reactions: To the medication or any of its ingredients

See our detailed guide on contraindications and who is not eligible for more information.

Safety Monitoring

Our registered pharmacist ensures your safety through:

Initial Assessment: Comprehensive medical history review before prescribing
Regular Follow-ups: Scheduled check-ins to monitor your progress
Side Effect Management: Guidance on managing any side effects you experience
Dosage Adjustments: Modifying your treatment plan as needed
Emergency Support: Available for urgent concerns or questions

Clinical Trial Safety Data

Both medications have been extensively studied:

Mounjaro: SURMOUNT trials involving over 2,500 patients over 72 weeks
Wegovy: STEP trials involving over 4,500 patients over 68 weeks
Safety Profile: Most side effects were mild to moderate and temporary
Serious Events: Low incidence of serious adverse events

Drug Interactions

Our pharmacist reviews all your current medications during consultation to check for potential interactions. It's important to inform us of all medications, supplements, and vitamins you're taking.

Learn more about Mounjaro safety specifically.

Frequently Asked Questions

Are weight loss medications safe?

Yes, when prescribed and monitored by a registered pharmacist. Mounjaro and Wegovy are FDA-approved medications with extensive clinical trial data supporting their safety and efficacy.

What are the common side effects?

Common side effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain. These are usually mild and temporary, occurring most often when starting treatment.

Who should not take weight loss medications?

Treatment is not suitable for people with medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or those who are pregnant or breastfeeding.

How is safety monitored during treatment?

Our registered pharmacist monitors your progress through regular follow-ups, reviews any side effects, and adjusts treatment as needed to ensure your safety throughout the treatment period.

Are there long-term safety concerns?

Both Mounjaro and Wegovy have been studied in clinical trials for extended periods (up to 72 weeks) with favourable safety profiles. Ongoing studies continue to monitor long-term safety.